Avatrombopag for the treatment of thrombocytopenia (low platelets) in adults with chronic liver disease who are planning surgery.

【Summary】

Avatrombopag is known as a small molecule thrombopoietin receptor (C-MPL) agonist that increases platelet counts without activating platelets, which reduces the need for transfusions. It works by telling the body to produce more platelets. It is currently used to treat thrombocytopenia in patients with chronic (ongoing) liver disease. It may also be used to treat thrombocytopenia in patients with chronic immune thrombocytopenia (a persistent condition that may cause abnormal bruising or bleeding due to an abnormally low number of platelets in the blood).

【Indications】

Treatment of thrombocytopenia (low platelets) in adults with chronic liver disease who are planning surgery.

【Specification】

20mg/tablet, 28 tablets/box.

【Storage】

Store at 20°C to 25°C (68°C to 77°F); short-distance transport is permitted at a temperature range of 15 to 30°C (59–86°F).

【Usage and Dosage】

Avatrombopag is an oral tablet. It is used to treat thrombocytopenia in patients with chronic liver disease who are scheduled to undergo surgery. It is usually taken once daily for 5 days starting 10 to 13 days before surgery.

For the treatment of thrombocytopenia in patients with ITP, take as directed by your doctor, usually once daily with food.

【side effect】

Avatrombopag may cause side effects. Common side effects include extreme fatigue, headache, nosebleeds or bleeding gums, and joint pain.

Serious side effects include: swelling, pain, redness of the hands, feet, or legs; shortness of breath, fever, cough, chest pain or rapid heartbeat, stomach pain, etc.

【Mechanism of action】

Avatrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist that stimulates megakaryocyte proliferation and differentiation from bone marrow progenitor cells, leading to increased platelet production. Avatrombopag is non-competitive with thrombopoietin in binding to the TPO receptor and has an additive pharmacological effect with TPO on platelet production.

Avatrombopag is a thrombopoietin receptor (TPOR) agonist with possible megakaryopoiesis stimulating activity. Following administration, avatrombopag binds to and stimulates the platelet thrombopoietin receptor (TPOR), which can lead to the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells. This process increases platelet production and may help prevent chemotherapy-induced thrombocytopenia. TPOR is classified as a member of the cytokine receptor and hematopoietin receptor superfamily.